The authors suggested that an important role of Down syndrome critical region 1 (DSCR1) in microglial activation is to provide a potential therapeutic target for microglial Aβ clearance in Alzheimer’s disease. The gene discussed is RCAN1; the disease is early-onset autosomal dominant Alzheimer disease.